Pursuant to the authorization granted by the annual general meeting on
The purpose of the issue and the repurchase of series C shares is to, when the series C shares have been converted to ordinary shares, ensure delivery of performance shares to employees within the BONESUPPORT group who are participating in the share saving program LTI 2020, which was adopted by the annual general meeting on
Since previously, BONESUPPORT holds 1,235,000 own series C shares. The series C shares carry one-tenth of a vote per share and do not entitle to dividends.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se
This information was submitted for publication, through the agency of the contact persons set out above, at 18.00 CET on
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in
BONESUPPORT and CERAMENT are registered trademarks of
https://news.cision.com/bonesupport-holding-ab/r/issue-and-repurchase-of-series-c-shares-for-share-saving-program,c3306721
https://mb.cision.com/Main/16090/3306721/1387037.pdf
(c) 2021 Cision. All rights reserved., source